NextCure Inc. and Simcere Zaiming Announce Strategic Partnership to Develop Novel Antibody-Drug Conjugate Targeting CDH6
Reuters
Jun 16
NextCure Inc. and Simcere Zaiming Announce Strategic Partnership to Develop Novel Antibody-Drug Conjugate Targeting CDH6
NextCure Inc., a clinical-stage biopharmaceutical company, has entered a strategic partnership with Simcere Zaiming, an oncology-focused biopharmaceutical company, to develop SIM0505, a novel antibody-drug conjugate $(ADC)$ targeting CDH6 for the treatment of solid tumors. Under the agreement, NextCure gains global rights to SIM0505, excluding greater China, where Simcere Zaiming will retain rights. SIM0505 is currently undergoing Phase 1 clinical testing in China, with plans for U.S. clinical trials to begin in the third quarter of 2025. This collaboration also grants NextCure access to Simcere Zaiming's proprietary linker and payload for use in an ADC directed to a novel target by NextCure, while Simcere Zaiming maintains rights in greater China. Simcere Zaiming is eligible for payments up to $745 million, along with tiered royalties on net sales outside of greater China. This partnership aims to accelerate drug development and provide new cancer therapies to patients globally.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCure Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9468709-en) on June 16, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.